trending Market Intelligence /marketintelligence/en/news-insights/trending/mGKh0OCtBza2hh5byLjuGQ2 content esgSubNav
In This List

Patent protection challenge to delay Novartis' psoriasis biosimilar

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes

Blog

Investment Banking Essentials Newsletter April Edition - 2022


Patent protection challenge to delay Novartis' psoriasis biosimilar

The sale of Novartis AG's biosimilar copy of Amgen Inc.'s Enbrel will be delayed to 2018 due to a patent protection challenge in U.S. federal court, Reuters reported Jan. 25.

The U.S. FDA has already approved the biosimilar copy of Enbrel, called Erelzi, for rheumatoid arthritis, plaque psoriasis, ankylosing spondylitis and other diseases. But Amgen claims that the drug has patent protection until 2029.

Richard Francis, head of Novartis' Sandoz generics business, reportedly stated that the legal battle could take at least a year.